HCW Biologics has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $2,500,005.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, HCW Biologics is raising $2,500,005.00 in new funding. About HCW Biologics: HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company’s lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
To learn more about HCW Biologics, visit http://hcwbiologics.com/
Contact:
Hing Wong, Chief Executive Officer
954-842-2024
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.